1. Home
  2. News
Cipla partners with ImmunoACT to launch talicabtagene autoleucel, an anti-CD19 CAR-T cell therapy for blood cancers in Africa

Cipla partners with ImmunoACT to launch talicabtagene autoleucel, an anti-CD19 CAR-T cell therapy for blood cancers in Africa

Cipla Limited (BSE: 500087; NSE: CIPLA; and hereafter referred to as “Cipla”), through its subsidiary Medpro Pharmaceutica, has entered into an exclusive license and supply agreement with Immunoadoptive Cell Therapy Private Limited (ImmunoACT). Under this partnership, Cipla will commercialize talicabtagene autoleucel, India’s first indigenously developed CAR-T cell therapy, in the Republic of South Africa, Algeria, and Morocco.

SURGEONS FOR LITTLE LIVES

SURGEONS FOR LITTLE LIVES

A decade of hope and healing: Surgeons for Little Lives marks 10 years of transforming paediatric care
Every day for ten years, Surgeons for Little Lives has stood beside children and families, providing life-saving care and support.

Meet the latest viral sensation – Flumune C

Meet the latest viral sensation – Flumune C

Meet the latest viral sensation – Flumune C If you’ve ever stared at the endless wall of effervescents at any pharmacy, desperately Googling “best immune booster for adults” only to come out more confused, you’re not alone. Once a simple place, the immune booster...

New multivitamin pulls the plug on nutrient waste

New multivitamin pulls the plug on nutrient waste

New multivitamin pulls the plug on nutrient waste Have you ever wondered what causes that highlighter yellow urine you see after taking a multivitamin? What you are seeing is some of the vitamins you took just hours ago being flushed down the loo. This is exactly the...